FMP

FMP

Enter

BNTX - BioNTech SE

photo-url-https://images.financialmodelingprep.com/symbol/BNTX.png

BioNTech SE

BNTX

NASDAQ

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

102.43 USD

-1.72 (-1.68%)

Historical Prices

From:

To:

100.01100.5101101.5102102.5103103.509:30 AM09:49 AM10:09 AM10:28 AM10:47 AM11:06 AM11:25 AM11:44 AM12:03 PM12:23 PM12:44 PM01:05 PM01:24 PM01:43 PM02:03 PM02:24 PM02:43 PM03:03 PM03:22 PM03:41 PM

About

ceo

Dr. Ugur Sahin M.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122),...

CIK

0001776985

ISIN

US09075V1026

CUSIP

09075V102

Address

An der Goldgrube 12

Phone

49 6131 9084 0

Country

DE

Employee

6,772

IPO Date

Oct 10, 2019

Financial Statement

-1B-500M0500M1B1.5B2023 Q42024 Q12024 Q22024 Q32024 Q4RevenueNet Income

Earnings

-4-3-2-101232023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q42025 Q1EPS Consensus

BNTX Financial Summary

CIK

0001776985

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

09075V102

ISIN

US09075V1026

Country

DE

Price

102.43

Beta

1.08

Volume Avg.

1.08M

Market Cap

24.62B

Shares

-

52-Week

76.53-131.49

DCF

93.77

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-32.41

P/B

-

Website

https://www.biontech.de

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest BNTX News

Rayan Ahmad

Mar 7, 2025

BioNTech SE (NASDAQ:BNTX) Earnings Preview and Financial Hea...

BioNTech SE, trading on the NASDAQ under the symbol BNTX, is a biotechnology company known for its work in developing mRNA-based vaccines and therapies. The company gained significant attention for its collaboration with Pfizer in developing a COVID-19 vaccine. BioNTech competes with other biotech firms like Moderna and CureVac in the mRNA space. BioNTech is set to release its fourth-quarter earnings on March 10, 2025, before the market opens. Analysts expect the company to report earnings per ...

Skynews

Aug 22, 2024

Lung cancer patient is first in UK to receive experimental v...

A lung cancer patient has become the first in the UK to receive a new experimental vaccine to help his body fight the disease.

Seeking Alpha

Aug 20, 2024

BioNTech: Clinical Hold Removal Pushes ADC Development Progr...

Partial clinical hold of BioNTech SE's BNT326/YL202 for the treatment of patients with solid tumors in phase 1 study was lifted by the FDA. The primary endpoint of ORR of BNT111 in combination with Libtayo, for the treatment of patients with anti-PD-1/anti-PD-L1 relapsed/refractory or unresectable stage III or IV melanoma, met with statistical significance. Positive results obtained from an open-label phase 2 study, using BNT311 + Keytruda for the treatment of patients with relapsed/refractory m...

The Motley Fool

Aug 19, 2024

Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time...

Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve non-inferiority when compared to an approved flu vaccine.

Investopedia

Aug 16, 2024

Pfizer, BioNTech Combination Flu and COVID-19 Shot Misses 1 ...

Shares of Pfizer (PFE) and American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmakers' combined COVID-19 and flu vaccine in adults.

Reuters

Aug 16, 2024

Pfizer, BioNtech say combined flu-COVID vaccine misses a mai...

Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 found the combination shot failed to meet one of the study's two main goals and they are evaluating next steps.

InvestorPlace

Aug 8, 2024

3 Biotech Stocks With Promising Drug Pipelines: August 2024

Investing in biotech stocks with promising pipelines has to be the most exciting area of the market. A successful drug approval can not only unveil a blockbuster treatment worth billions of dollars, but it can literally change people's lives for the better.

Seeking Alpha

Aug 6, 2024

BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Desp...

BioNTech SE reported Q2 2024 earnings yesterday, with a significant decrease in revenues from Comirnaty compared to previous years. The company reaffirmed guidance for 2024, for revenues of $2.7bn — $3.4bn, but is expecting a loss-making year due to increased costs. The cash position remains healthy at nearly $20bn, which helps to support a $19.5bn market cap valuation at the present times.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep